Das Barshan A, Matsumoto-Takahashi E
JMA J. 2024; 7(2):153-171.
PMID: 38721084
PMC: 11074501.
DOI: 10.31662/jmaj.2023-0171.
Harandi H, Fallahtafti P, Karimi A, Hashemi S, Mahalleh M, Ashouri M
BMC Geriatr. 2024; 24(1):411.
PMID: 38720296
PMC: 11080142.
DOI: 10.1186/s12877-024-05006-0.
Meejun T, Srisurapanont K, Manothummetha K, Thongkam A, Mejun N, Chuleerarux N
Blood Adv. 2023; 7(18):5624-5636.
PMID: 37389818
PMC: 10514108.
DOI: 10.1182/bloodadvances.2023010349.
Mancuso K, Zamagni E, Solli V, Gabrielli L, Leone M, Pantani L
Front Oncol. 2023; 13:1208741.
PMID: 37305577
PMC: 10249866.
DOI: 10.3389/fonc.2023.1208741.
Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F
Leukemia. 2023; 37(6):1175-1185.
PMID: 37142661
PMC: 10157596.
DOI: 10.1038/s41375-023-01920-1.
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.
Uaprasert N, Pitakkitnukun P, Tangcheewinsirikul N, Chiasakul T, Rojnuckarin P
Blood Cancer J. 2022; 12(12):173.
PMID: 36550105
PMC: 9780106.
DOI: 10.1038/s41408-022-00776-5.
Amyloidosis and COVID-19: experience from an amyloid program in Canada.
Lewis E, Fine N, Miller R, Hahn C, Chhibber S, Mahe E
Ann Hematol. 2022; 101(10):2307-2315.
PMID: 36028582
PMC: 9417080.
DOI: 10.1007/s00277-022-04964-y.
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
Noori M, Azizi S, Abbasi Varaki F, Nejadghaderi S, Bashash D
Int Immunopharmacol. 2022; 110:109046.
PMID: 35843148
PMC: 9273573.
DOI: 10.1016/j.intimp.2022.109046.
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
Wagner A, Garner-Spitzer E, Schotta A, Orola M, Wessely A, Zwazl I
Front Immunol. 2022; 13:889138.
PMID: 35634285
PMC: 9133631.
DOI: 10.3389/fimmu.2022.889138.
Lack of Induction of RBD-Specific Neutralizing Antibodies despite Repeated Heterologous SARS-CoV-2 Vaccination Leading to Seroconversion and Establishment of T Cell-Specific Memory in a Patient in Remission of Multiple Myeloma.
Kratzer B, Trapin D, Gattinger P, Oberhofer T, Sehgal A, Waidhofer-Sollner P
Vaccines (Basel). 2022; 10(3).
PMID: 35335006
PMC: 8949333.
DOI: 10.3390/vaccines10030374.
